Clinical trial NCT02331706: IFN-DLI for Relapsed Acute Leukemia After Allo-SCT
Official title: A Pilot Study to Determine the Feasibility of Conventional Induction Chemotherapy Followed by G-CSF Mobilized Donor Leukocyte Infusion (DLI) and IFN-α (IFN-DLI) for Relapsed Acute Leukemia After Allogeneic Stem Cell Transplantation.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: EARLY_PHASE1
Conditions: Leukemia
Lead sponsor: Abramson Cancer Center at Penn Medicine
Sponsor class: OTHER
First posted: 2015-01-06
Enrollment: 16
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This trial is designed to determine the feasibility of conventional induction chemotherapy, IFNand G-CSF mobilized DLI (IFN-DLI) in subjects with relapsed AML and ALL after allo-SCT.


Eligibility criteria: Inclusion Criteria:

DLI Recipient

* Relapsed AML or ALL ≥ 60 days after allogeneic SCT.
* Evidence of residual donor chimerism on most recent analysis (within 4 weeks of enrollment).
* Age ≥ 18 years of age,
* Karnofsky performance status ≥ 60%.
* Absence of active GVHD and off immunosuppression. Subjects on tapering prednisone will be eligible if their dose is 0.25 mg/kg or less and being actively tapered. We suggest a 28 day waiting period off of immunosuppression but some subjects with rapidly progressive disease may need to be treated before 30 days and will still be eligible.
* Adequate organ function: Cr ≤ 2 mg/dL; ALT/AST \< 3x ULN, direct bili \<3x ULN.
* Matched sibling or un-related donor (A, B, C, and DR) available to undergo leukopheresis.
* Subjects must be able to sign consent and be willing and able to comply with scheduled visits, treatment plan and laboratory testing.
* Willing to provide blood samples for research purposes.
* Willing to adhere to medically accepted form of birth control to prevent pregnancy (includes: complete abstention from intercourse, condoms, diaphragms, cervical cap, intra-uterine device, history of surgical sterility - tubal ligation or vasectomy in patient or partner, or oral contraceptive).

DLI Donor

1. HLA identical to recipient subject.
2. Considered medically eligible for leukopheresis procedure by independent donor physician (University of Pennsylvania physician who is not the recipient's primary transplant physician for related donors; physician designated by National Marrow Donor Program for unrelated donors).
3. Considered medically eligible to receive G-CSF (filgrastim) by independent donor physician.

Exclusion Criteria

Recipient

* Prior cell therapy for relapse within the past 90 days.
* Requirement for active immunosuppression to treat GVHD.
* Pregnant or lactating women. The safety of this therapy on unborn children and effects on breast milk are not known.
* Uncontrolled active infection
* Any uncontrolled active medical disorder that would preclude participation as outlined.

Donor

- Unable to participate in a leukopheresis procedure or receive G-CSF (filgrastim).

Primary outcomes:
measure: Number of Adverse Events
timeFrame: 2 years
Secondary outcomes:
measure: overall survival
timeFrame: 2 years
measure: disease-free survival
timeFrame: 2 years
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: Abramson Cancer Center of the University of Pennsylvania
state: Pennsylvania
Study officials:
affiliation: Abramson Cancer Center at Penn Medicine
name: David Porter, MD
role: PRINCIPAL_INVESTIGATOR
References: